Understanding the Treatment of Waldenström's Macroglobulinemia
Ibrutinib proved to be a “game changer” in Waldenström’s macroglobulinemia, having yielded an overall response rate of 90% and a major response rate of 73% in the pivotal trial.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers